Analysis | Metabolite Name | Measured Value | Units | Sample source | Condition | Symptom |
---|---|---|---|---|---|---|
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 107 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 168 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 170 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 188 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 193 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 196 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 209 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 214 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 216 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 239 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 272 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 275 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 285 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 286 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 286 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 295 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 337 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 339 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 341 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 347 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 350 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 381 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 390 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 406 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 413 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 445 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 446 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 475 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 530 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 545 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 564 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 586 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 595 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 596 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 599 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 608 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 628 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 635 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 659 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 682 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 686 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 693 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 697 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 706 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 735 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 785 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 813 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 816 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 818 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 831 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 844 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 859 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 860 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 862 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 878 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 885 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 942 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 982 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 989 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1000 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1011 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1012 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1021 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1074 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1104 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1132 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1201 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1209 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1268 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1296 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1302 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1314 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1324 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1426 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1442 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1467 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1478 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1483 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1495 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1514 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1547 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1561 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1593 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1626 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1649 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1711 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1727 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1759 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1836 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1846 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1876 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1939 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 1989 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2094 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2133 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2224 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2357 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2375 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2382 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2415 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2535 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2564 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2569 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2573 | Peak area | Plasma | Premenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2826 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 2932 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3030 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3161 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3169 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3207 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3208 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3405 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3430 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3772 | Peak area | Plasma | Postmenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 3894 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 4165 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 4170 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 4200 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 4429 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 4452 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 5127 | Peak area | Plasma | Postmenopause | Depression |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | 6815 | Peak area | Plasma | Premenopause | Control |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | Peak area | - | - | - | |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | Peak area | Plasma | Postmenopause | Control | |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | Peak area | Plasma | Postmenopause | Depression | |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | Peak area | Plasma | Premenopause | Control | |
Reversed phase UNSPECIFIED ION MODE | Azelaoyl-PAF | Peak area | Plasma | Premenopause | Depression |